Sanofi /Regeneron :Second Dupixent® (Dupilumab) Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease Improvements, Underscoring Role Of Type 2 Inflammation In This Complex Disease.Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease Improvements.Data Continue To Support Well-Established Safety Profile Of Dupixent.Encouraged That Dupixent, Which Targets Il-4 And Il-13, Was Able To Reduce Inflammation In Esophagus.Look Forward To Continuing Studying Dupixent'S Potential Role In Addressing Underlying Type 2 Inflammation That Can Lead To Eosinophilic Esophagitis.
免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。
